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OBJECTIVES: Despite available treatment options, chronic infection of individuals
with the hepatitis C virus (HCV), together with associated chronic liver diseases,
remains a significant public health burden in England and Wales. Fewer than half
of patients with genotype 1 chronic hepatitis C (CHC) achieve sustained virologic
response (SVR) following the current standard treatment with peginterferon alfa
and ribavirin. The aim of this analysis was to evaluate the cost-effectiveness of
boceprevir, a protease inhibitor, in combination with peginterferon alfa and riba-
virin, compared to peginterferon alfa and ribavirin alone, among treatment naïve
and previously treated patients with genotype 1 CHC in England and Wales.
METHODS: Specific treatment strategies for boceprevir have been outlined in the
UK licence for different patient groups. A Markov model was developed to evaluate
these treatment strategies for boceprevir triple-therapy compared to peginterferon
alfa and ribavirin alone, and to estimate the expected costs and health-related
quality of life benefits associated with them. The incremental cost-effectiveness of
including boceprevir in a new triple-therapy standard of care was assessed from
the perspective of the National Health Service and Personal Social Services over the
lifetime of the patient cohort. Clinical data inputs for each treatment strategy were
estimated based on subgroup analyses of the phase III trials for boceprevir.
RESULTS: The incremental cost-effectiveness ratio (ICER) for treatment-naïve pa-
tients was £11,601 when boceprevir triple-therapy was compared to current stan-
dard treatment with peginterferon alfa and ribavirin. For treatment-experienced
patients, the ICER with boceprevir triple-therapy was £2,909. These results were
robust to sensitivity analyses and below a threshold of £20,000. CONCLUSIONS:
The inclusion of boceprevir as part of a new triple-therapy standard of care for
patients with genotype 1 CHC is clinically efficacious and cost-effective, irrespec-
tive of whether patients have been previously treated. The use of boceprevir in this
setting is recommended by NICE.
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OBJECTIVES: Dual therapy with ribavirin and peg-interferon over a duration of
up to 72 weeks (W) has been the former standard of care in patients with chronic
Hepatitis C (HCV) genotype 1 and is still used in some patients. The aim of this
analysis is to evaluate the direct HCV-related costs and effects of dual therapy in
therapy-naïve and pretreated patients in Germany.METHODS: In this retrospec-
tive chart review study, dual therapy in patients with chronic HCV genotype 1 in
2008/2009 was evaluated in Germany. Data from patients treated with a combi-
nation of ribavirin and peg-interferon were retrospectively documented during
the treatment period and thereafter (on average 61 W of post-treatment follow-
up). A total of 208 therapy-naïve and 182 pretreated patients from 31 study sites
were included in the analysis. RESULTS: Mean time since first diagnosis of HCV
was 6.0 years and 10.4 years in therapy-naïve and pretreated patients, respec-
tively. 33.0% of pretreated patients were prior non responders, 37.9% were re-
lapsers. The average treatment duration during study was 42 W (SD 22W) both in
therapy-naïve and pretreated patients. Sustained virological response (SVR)
was demonstrated in 58.1% of therapy naïve and 36.6% of pretreated patients
with HCV-RNA measurements available (167 and 142 patients with measure-
ment, respectively). Mean per patient costs related to HCV during therapy from
the statutory health insurance perspective were 14,554€ (SD 9,139€) for therapy-
naïve and 14,590€ (SD 10,443€) for pretreated patients. Main cost-driver of treat-
ment was medication cost, accounting for 87% of total costs, followed by sick
leaves and diagnostics. Hospitalizations and physician visits played a less im-
portant role in terms of costs. CONCLUSIONS: Especially in pretreated patients,
HCV dual therapy is costly due to the low treatment success rate. This empha-
sizes the need for treatments with improved efficacy, minimizing costly non-
response resulting in potential cost savings.
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OBJECTIVES: To assess cost-effectiveness of adalimumab versus standard care
(SC) for treating patients with severely active Crohn’s disease (CD) in Germany
from a societal perspective. Additionally, cost-per-remitter for adalimumab was
estimated and compared with infliximab 5mg/kg maintenance therapy.
METHODS: To compare adalimumab to SC, a 4-disease-state clinical model (ie,
remission, moderate, severe, very severe) based on the Crohn’s Disease Activity
Index (CDAI) was constructed tracking patients over their lifetimes. The model
estimated direct costs, indirect costs, and quality-adjusted life-years (QALYs)
from the German societal perspective. Efficacy inputs for adalimumab were
based on actual observations from CHARM (Crohn’s Trial of the Fully Human
Antibody Adalimumab for Remission Maintenance). Using data from CLASSIC I
(Clinical Assessment of Adalimumab Safety and Efficacy Studied as Induction
Therapy in Crohn’s Disease), a regression model was used to predict efficacy of
SC. Direct/indirect costs and utility inputs were derived from public sources and
literature. To compare adalimumab to infliximab, cost-per-remitter was esti-
mated by dividing costs by the percentage of patients in remission on a yearly
basis. Remission rates of adalimumab and infliximab upon baseline matching
adjustment for patients with moderate-to-severe CD came from CHARM and
ACCENT I (A Crohn’s Disease Clinical Trial Evaluating Infliximab in a New Long-
Term Treatment Regimen), respectively. RESULTS: The incremental costs per
QALY gained for adalimumab versus SC were €37,270 (2012 Euro) over a lifetime
horizon in the base case. One-way sensitivity analyses varying key parameters
produced incremental costs per QALY gained ranging from €23,011–€51,528
when compared with SC. An average of 47.2% adalimumab-treated and 37.1%
infliximab-treated patients were in remission yearly. The corresponding cost-
per-remitter was €54,823 for adalimumab and €88,506 for infliximab.
CONCLUSIONS: Adalimumab appears to be cost-effective compared with SC for
treating patients with severely active CD. The cost-per-remitter for mainte-
nance therapy was less for adalimumab than for infliximab.
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OBJECTIVES: In patients with chronic infection with hepatitis C virus (HCV) geno-
type 1 who did not achieve a sustained response to the standard therapy with
peginterferon/ribavirin (PR) the combination of boceprevir (B) or telaprevir (T) plus
peginterferon alpha/ribavirin have shown to produce a higher rate of sustained
virologic response (SVR) than the retreatment with PR. The aim of this study is to
assess the cost effectiveness of these two (BPR and TPR) antiviral regimens.
METHODS: We developed a Markov model to describe the clinical history of previ-
ously treated HCV genotype 1 patients who did not achieve SVR in which one
cohort (1) receives PR for 4 weeks followed by BPR for 32 weeks and, those patients
with a detectable HCV RNA level at week 8 receive PR for an additional 12 weeks;
cohort 2 patients receive 12 weeks TPR followed by 36 weeks PR. All patients are
followed for their expected lifetime. The reference patient is 30-year-old with CHC
without cirrhosis. The SVRs to BPR and TPR cohorts came from RESPOND 2 and
REALIZE studies. Quality of life for each health state was based on literature. Costs
for each health state were based on three Delphi panels, one with hepatologists,
one with intensivists and another with oncologists. Costs in 2011 Brazilian Reais
and benefits were discounted at 3%. RESULTS: The combination BPR increases life
expectancy by 0.60 years and quality adjusted life years (QALY) by 0.89 years com-
pared to TPR. BPR is cheaper than TPR (-23,428 Brazilian Reais). CONCLUSIONS: In
Brazil, for the treatment of previously treated patients with HCV genotype 1 infec-
tion boceprevir plus peginterferon alpha/ribavirin is dominant compared with te-
laprevir plus peginterferon alpha/ribavirin.
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OBJECTIVES: The study compares the cost-effectiveness (CE) of dexlansoprazole
with other proton pump inhibitors (PPI) currently included in the Mexico National
Formulary (Positive List) for treatment of erosive esophagitis (EE). METHODS: A
decision tree with the 8-week temporal horizon was designed for patients over 18
with EE confirmed by endoscopy. The perspective taken is that of second-level
public health institutions. Treatment alternatives modelled are dexlansoprazole 60
mg/day, esomeprazole 40 mg/day; omeprazole 20 mg/day, pantoprazole 40mg/day,
rabeprazole 20 mg/day. Possible outcomes considered were healing or not healing,
the latter possibly leading to surgery. Costs included in the model were treatment
regimens, consult, endoscopy, surgery (when necessary), and hospitalization days
(when necessary) and were taken from official or published sources. Effectiveness
was measured in terms of percentage of patients with healed oesophagus. A
weighted average of effectiveness was calculated for use in the model. One-way
sensitivity analyses of cost and effectiveness variables and a Monte Carlo (MC)
simulation of a 1000 cohorts were also conducted to test the robustness of the
results. RESULTS: Compared to all PPIs modelled/tested, dexlansoprazole was
highly dominant, being more effective (0.9270) and less costly (USD$ 1.27 per day),
even when compared to omeprazole’s USD$ 0.015 per DDD. It was therefore not
considered necessary to calculate the Incremental Cost-Effectiveness Ratio (ICER)
since these would be negative. The sensitivity analyses and Monte Carlosimula-
tions found omeprazole to be the second-best alternative, and actually dominant
in 16.7% of the MC simulations. CONCLUSIONS: Dexlansoprazole was found to be
dominant compared to all PPIs evaluated for EE, being both more effective and less
costly for public institutions in Mexico.
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